SoylentNews is people
SoylentNews
from the lucy-in-the-sky-with-diamonds dept.
Beginning in the nineteen-fifties, psychedelics had been used to treat a wide variety of conditions, including alcoholism and end-of-life anxiety. The American Psychiatric Association held meetings centered on LSD. Some of the best minds in psychiatry had seriously studied these compounds in therapeutic models, with government funding.
Between 1953 and 1973, the federal government spent four million dollars to fund a hundred and sixteen studies of LSD, involving more than seventeen hundred subjects. Through the mid-nineteen-sixties, psilocybin and LSD were legal and remarkably easy to obtain. Sandoz, the Swiss chemical company, gave away large quantities of Delysid—LSD—to any researcher who requested it, in the hope that someone would discover a marketable application.
Now, forty years after the Nixon Administration effectively shut down most psychedelic research, the government is gingerly allowing a small number of scientists to resume working with these powerful and still somewhat mysterious molecules.
(Score: 3, Informative) by Anonymous Coward on Wednesday February 11 2015, @05:39PM
Even "liberal" news outlets can't handle it [nytimes.com]:
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. [nih.gov]
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. [nih.gov]
Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca. [nih.gov]
A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects. [nih.gov]
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. [nih.gov]
LSD enhances suggestibility in healthy volunteers. [nih.gov]
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. [nih.gov]
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. [nih.gov]
History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). [nih.gov]
Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia. [nih.gov]
From Hofmann to the Haight Ashbury, and into the future: the past and potential of lysergic acid diethlyamide. [nih.gov]
Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. [nih.gov]
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. [nih.gov]
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. [nih.gov]
Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction. [nih.gov]
Can psychedelic compounds play a part in drug dependence therapy? [nih.gov]
Psilocybin and Obsessive Compulsive Disorder. [nih.gov]
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. [nih.gov]
Enhanced repertoire of brain dynamical states during the psychedelic experience. [nih.gov]
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. [nih.gov]
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. [nih.gov]
The Heffter Research Institute: past and hopeful future. [nih.gov]